Atlas Trials

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Clinical trial NCT03125200 · TERMINATED

Trial details

NCT number
NCT03125200
Sponsor
ADC Therapeutics S.A.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast CancerNon Small Cell Lung CancerGastroEsophageal CancerBladder Cancer
Start date
2017-05-18
Primary completion
2018-04-05
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.